Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers
- PMID: 23032411
- PMCID: PMC3660105
- DOI: 10.1097/QAD.0b013e32835a9950
Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers
Abstract
HIV-1 elite controllers spontaneously maintain suppressed levels of viremia, but exhibit significant immune activation. We investigated coronary atherosclerosis by coronary computed tomography angiography (CTA) in elite controllers, nonelite controller, chronically HIV-1 infected, antiretroviral therapy (ART)-treated patients with undetectable viral load ('chronic HIV'), and HIV-negative controls. Prevalence of atherosclerosis (78 vs. 42%, P < 0.05) and markers of immune activation were increased in elite controllers compared with HIV-negative controls. sCD163, a monocyte activation marker, was increased in elite controllers compared with chronic HIV-1 (P < 0.05) and compared with HIV-negative controls (P < 0.05). These data suggest a significant degree of coronary atherosclerosis and monocyte activation among elite controllers.
Similar articles
-
Evidence for innate immune system activation in HIV type 1-infected elite controllers.J Infect Dis. 2014 Mar;209(6):931-9. doi: 10.1093/infdis/jit581. Epub 2013 Nov 1. J Infect Dis. 2014. PMID: 24185941 Free PMC article.
-
HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses.AIDS. 2010 May 15;24(8):1095-105. doi: 10.1097/QAD.0b013e3283377a1e. AIDS. 2010. PMID: 20400885 Free PMC article.
-
Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.J Infect Dis. 2008 Jan 1;197(1):126-33. doi: 10.1086/524143. J Infect Dis. 2008. PMID: 18171295 Free PMC article.
-
HIV controllers: to treat or not to treat? Is that the right question?Lancet HIV. 2019 Dec;6(12):e878-e884. doi: 10.1016/S2352-3018(19)30264-4. Epub 2019 Oct 14. Lancet HIV. 2019. PMID: 31624011 Review.
-
Characteristics of plasmacytoid dendritic cell and CD4+ T cell in HIV elite controllers.Clin Dev Immunol. 2012;2012:869505. doi: 10.1155/2012/869505. Epub 2012 Nov 21. Clin Dev Immunol. 2012. PMID: 23243424 Free PMC article. Review.
Cited by
-
Th17 and Th17/Treg ratio at early HIV infection associate with protective HIV-specific CD8(+) T-cell responses and disease progression.Sci Rep. 2015 Jun 23;5:11511. doi: 10.1038/srep11511. Sci Rep. 2015. PMID: 26099972 Free PMC article.
-
Unravelling the mechanisms of durable control of HIV-1.Nat Rev Immunol. 2013 Jul;13(7):487-98. doi: 10.1038/nri3478. Nat Rev Immunol. 2013. PMID: 23797064 Review.
-
E-Selectin and markers of HIV disease severity, inflammation and coagulation in HIV-infected treatment-naïve individuals.Afr Health Sci. 2018 Dec;18(4):1066-1075. doi: 10.4314/ahs.v18i4.28. Afr Health Sci. 2018. PMID: 30766573 Free PMC article.
-
Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers.PLoS Pathog. 2013;9(10):e1003691. doi: 10.1371/journal.ppat.1003691. Epub 2013 Oct 10. PLoS Pathog. 2013. PMID: 24130489 Free PMC article. Clinical Trial.
-
Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection.J Am Heart Assoc. 2020 Feb 4;9(3):e014873. doi: 10.1161/JAHA.119.014873. Epub 2020 Jan 24. J Am Heart Assoc. 2020. PMID: 31973607 Free PMC article. Review. No abstract available.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical